209 related articles for article (PubMed ID: 14987532)
1. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
León P; Pozo F; Echevarría JM
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
[TBL] [Abstract][Full Text] [Related]
2. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
[TBL] [Abstract][Full Text] [Related]
3. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Ayres A; Bartholomeusz A; Lau G; Lam KC; Lee JY; Locarnini S
J Clin Virol; 2003 May; 27(1):111-6. PubMed ID: 12727536
[TBL] [Abstract][Full Text] [Related]
5. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
[TBL] [Abstract][Full Text] [Related]
6. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
[TBL] [Abstract][Full Text] [Related]
7. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
[TBL] [Abstract][Full Text] [Related]
8. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
[TBL] [Abstract][Full Text] [Related]
9. Current pharmacotherapy for the treatment of chronic hepatitis B.
Lagget M; Rizzetto M
Expert Opin Pharmacother; 2003 Oct; 4(10):1821-7. PubMed ID: 14521491
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant.
Tang S; Ho SK; Moniri K; Lai KN; Chan TM
Transplantation; 2002 Jan; 73(1):148-51. PubMed ID: 11792996
[TBL] [Abstract][Full Text] [Related]
11. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
12. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
Feng B; Wei L; Chen M; Wang L
Microbiol Res; 2008; 163(4):487-92. PubMed ID: 17317127
[TBL] [Abstract][Full Text] [Related]
13. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
14. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
15. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.
Lok AS; Zoulim F; Locarnini S; Mangia A; Niro G; Decraemer H; Maertens G; Hulstaert F; De Vreese K; Sablon E
J Clin Microbiol; 2002 Oct; 40(10):3729-34. PubMed ID: 12354872
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J
J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
[TBL] [Abstract][Full Text] [Related]
17. Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine.
Meisel H; Preikschat P; Reinke P; Hocher B; Budde K; Bechstein WO; Neuhaus P; Krüger DH; Neumayer HH
Transpl Int; 1999; 12(4):283-7. PubMed ID: 10460876
[TBL] [Abstract][Full Text] [Related]
18. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
19. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.
Lai CL; Yuen MF; Hui CK; Garrido-Lestache S; Cheng CT; Lai YP
J Med Virol; 2002 Jul; 67(3):334-8. PubMed ID: 12116023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
